Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Maria Pomponio"'
Autor:
Kevin Fox, Macy Goldbach, Jennifer M. Matro, Fei Xie, Maria Pomponio, Luke Keele, Lawrence N. Shulman, Amy S. Clark, Susanna M. Nazarian, Julia Tchou, Laura Burkbauer
Publikováno v:
Journal of Surgical Oncology. 121:447-455
Background We aim to compare the clinical outcomes of patients with early-stage HER2+ breast cancer treated with adjuvant chemotherapy (AC) and neoadjuvant chemotherapy (NAC). Methods Patients with non-metastatic HER2+ breast cancer treated from 2009
Autor:
Lawrence N. Shulman, Luke Keele, Julia Tchou, Amy S. Clark, Maria Pomponio, Kevin Fox, Jennifer M. Matro
Publikováno v:
Breast Cancer Research and Treatment. 177:137-143
A recent study reported that time to adjuvant chemotherapy (TTC) > 30 days was significantly associated with worse OS and DFS in triple-negative breast cancer (TNBC). Earlier studies, however, found that worse outcomes were associated with TTC > 60 d
Autor:
Laura Burkbauer, Susanna M. Nazarian, Yun Li, Macy Goldbach, Julia Tchou, Luke Keele, Maria Pomponio, Kelly C. Allison
Publikováno v:
Surgical oncology. 34
The 21-gene recurrence score (RS) is an established predictor of recurrence for early stage, hormone receptor positive breast cancer. The association between RS and other risk factors such as obesity has not been fully explored. We hypothesized that
Autor:
Kevin Fox, Elizabeth Hilt, Laura Burkbauer, Luke Keele, Macy Goldbach, Julia Tchou, Susanna M. Nazarian, Maria Pomponio
Publikováno v:
Annals of surgical oncology. 27(5)
Prior to the advent of Oncotype DX 21-gene recurrence score (oDX) assay, the National Comprehensive Cancer Network (NCCN) guideline supported omission of adjuvant chemotherapy in patients with ≤ 1 cm (T1b) hormone receptor-positive (HR +), human ep
Publikováno v:
Journal of the American College of Surgeons. 229:e76-e77
Publikováno v:
Journal of the American College of Surgeons. 229:S38
Publikováno v:
Journal of the American College of Surgeons. 229:e7